Overview

Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)

Status:
Active, not recruiting

Trial end date:
2023-01-10

Target enrollment:

Participant gender:

Summary

The purpose of this study is to compare the objective response rate, progression free survival and the overall survival of Nivolumab combined with Ipilimumab to Sunitinib monotherapy in patients with previously untreated Renal Cell Cancer.

Phase:

Phase 3

Details

Lead Sponsor:

Bristol-Myers Squibb

Collaborator:

Ono Pharmaceutical Co. Ltd

Treatments:

Antibodies, Monoclonal
Ipilimumab
Nivolumab
Sunitinib